PF-04691502

DRUG3 trials

Sponsors

Pfizer

Conditions

Advanced Breast Cancer (Phase 1b)Breast NeoplasmsCancerEarly Breast Cancer (Phase 2)

Phase 1

A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

CompletedNCT00927823

Start: 2009-12-31End: 2012-04-30Updated: 2014-08-12

Phase 2

Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer

TerminatedNCT01430585

PfizerAdvanced Breast Cancer (Phase 1b), Early Breast Cancer (Phase 2)

Start: 2012-03-31End: 2012-12-31Updated: 2014-08-12

Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer

WithdrawnNCT01658176

PfizerBreast Neoplasms

Start: 2013-01-31End: 2015-04-30Updated: 2012-10-29